Wrap Text
Transactions by persons discharging managerial responsibilities
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
(“Mediclinic”, the “Company”, or the “Group”)
23 July 2021
NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL
RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
On 21 July 2021, Jurgens Myburgh, Group Chief Financial Officer, acquired 4 000 shares in the
Company at a price of ZAR57.06 per share. Subsequently, on 22 July 2021, Dr Ronnie van der Merwe,
Group Chief Executive Officer, acquired 10 000 shares in the Company at a price of ZAR57.02 per
share.
These purchases were made following the vesting on 20 July 2021 of awards made under the
Company’s Short Term Incentive scheme, which were settled in cash in accordance with the
remuneration policy that applied at the time the awards were granted, as set out in the announcement
issued on 21 July 2021 (RNS number 9636F). Consistent with that policy, both directors have applied
proceeds from the vesting towards purchasing shares in the Company to continue building up their
shareholding towards their minimum shareholding guidelines under the current remuneration policy.
Following these transactions, Jurgens Myburgh and Ronnie van der Merwe now own a total of 94 500
and 61 630 shares, respectively, in Mediclinic.
The following notifications are made in accordance with Articles 19.1 and 19.3 of the Market Abuse
Regulation.
1. Details of PDMR / persons closely associated with them (“PCA”)
a) Name Carel Aron van der Merwe
2. Reason for the notification
a) Position / status Group Chief Executive Officer
b) Initial notification / Initial notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or
auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each
type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Purchase of shares
transaction
c) Price(s) and
volume(s) Price(s) per share Volume(s)
ZAR57.02 10 000
d) Aggregated
information
Aggregated volume 10 000
Price ZAR57.02 per share
e) Date of the 22 July 2021
transaction
f) Place of the Johannesburg Stock Exchange
transaction
1. Details of PDMR / persons closely associated with them (“PCA”)
a) Name Mr Petrus Jurgens Myburgh
2. Reason for the notification
a) Position / status Group Chief Financial Officer
b) Initial notification / Initial notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or
auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each
type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Purchase of shares
transaction
c) Price(s) and
volume(s) Price(s) per share Volume(s)
ZAR57.06 2 524
ZAR57.06 1 476
d) Aggregated
information
Aggregated volume 4 000
Price ZAR57.06 per share
e) Date of the 21 July 2021
transaction
f) Place of the Johannesburg Stock Exchange
transaction
About Mediclinic International plc
Mediclinic is a diversified international private healthcare services group, established in South Africa
in 1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab
Emirates (“UAE”).
The Group’s core purpose is to enhance the quality of life.
Its vision is to be the partner of choice that people trust for all their healthcare needs.
Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the
continuum of care in such a way that the Group will be regarded as the most respected and trusted
provider of healthcare services by patients, medical practitioners, funders and regulators of healthcare
in each of its markets.
At 31 March 2021, Mediclinic comprised 74 hospitals, five subacute hospitals, two mental health
facilities, 18 day case clinics and 18 outpatient clinics. Hirslanden operated 17 hospitals and four day
case clinics in Switzerland with more than 1 900 inpatient beds; Mediclinic Southern Africa operations
included 50 hospitals (three of which in Namibia), five sub-acute hospitals, two mental health facilities
and 12 day case clinics (four of which operated by Intercare) across South Africa, and around 8 600
inpatient beds; and Mediclinic Middle East operated seven hospitals, two day case clinics and 18
outpatient clinics with more than 900 inpatient beds in the UAE. In addition, under management
contracts, Mediclinic Middle East operates one hospital in Abu Dhabi and will open a 200-bed hospital
in the Kingdom of Saudi Arabia in mid-2022.
The Company’s primary listing is on the London Stock Exchange (“LSE”) in the United Kingdom, with
secondary listings on the JSE in South Africa and the Namibian Stock Exchange in Namibia.
Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare
group based in the United Kingdom and listed on the LSE.
For further information, please contact:
Company Secretary, Link Company Matters Limited
Caroline Emmet
+44 (0)333 300 1930
Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181
Media queries
FTI Consulting
Ben Atwell/Ciara Martin – United Kingdom
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000
Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Corporate broker (United Kingdom): Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd
Date: 23-07-2021 04:00:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
Sharenet Sites 
